Last updated: March 2, 2026
What is NDC 72485-0630?
NDC 72485-0630 corresponds to Vasopressin (Vasostrict), a synthetic form of the natural hormone vasopressin used primarily for vasodilatory shock, vasoconstriction, and in certain cases of hemorrhage. It is supplied as a sterile solution administered intravenously.
Market Size and Demand Dynamics
Historical Revenue and Market Trends
- The global vasopressin market was valued at approximately $0.5 billion in 2021.
- Growth rate from 2017 to 2021 averaged 4% annually, driven by increasing cases of septic shock and advancements in critical care practices.
Key Drivers
- Rising prevalence of septic shock, involving vasopressors for hemodynamic stability.
- Growth in ICU admissions globally.
- Expanding hospital infrastructure, especially in emerging markets.
- Price sensitivity driven by formulary decisions in hospitals and insurance reimbursement policies.
Major Market Segments
| Region |
Market Share (2022) |
Growth Rate (2022-2027) |
Key Factors |
| United States |
45% |
3.5% |
High ICU utilization, familiarity with vasopressors |
| Europe |
30% |
4.2% |
Increasing critical care needs, reimbursement policies |
| Asia-Pacific |
15% |
6.0% |
Growing healthcare infrastructure, expanding ICU capacity |
| Rest of World |
10% |
3.8% |
Limited access, improving healthcare infrastructure |
Competitive Landscape
Major pharmaceutical companies involved:
- Ferring Pharmaceuticals (brand: Vasostrict)
- Hikma Pharmaceuticals
- Mylan (acquired by Viatris)
- Teva Pharmaceuticals
Market share is concentrated among these firms, with Ferring as the dominant player.
Pricing Landscape and Projections
Current Price Points
- The average wholesale price (AWP) for a 1 mL vial of vasopressin (100 units/mL) in the US ranges from $100 to $150.
- Public hospital pricing is lower, roughly $50 to $70 per vial, depending on volume and negotiated discounts.
- In Europe, prices are comparable but can vary by country and reimbursement status.
Factors Affecting Price Dynamics
- Patent expiration related to branded formulations is not imminent but could influence generic competition over the next 3-5 years.
- Supply chain constraints, especially post-pandemic, can affect availability and pricing.
- Reimbursement policies influence net prices for hospitals and clinics.
Price Projections (2023-2028)
| Year |
Estimated Price Range (per vial) |
Key Influences |
| 2023 |
$60 - $150 |
Stable demand; potential supply chain effects |
| 2024 |
$60 - $140 |
Entry of generics; price competition emerges |
| 2025 |
$55 - $130 |
Increased generic market penetration |
| 2026 |
$50 - $125 |
Market saturation; prices stabilize |
| 2027 |
$50 - $120 |
Reimbursement adjustments; stable competition |
Outlook Summary
The price of vasopressin is expected to decline modestly as generic competition increases, especially after patent expiry, projected around 2027-2028. The variability in hospital procurement strategies and regional reimbursement policies will influence actual prices.
Regulatory and Policy Impact
- FDA approval was granted for synthetic vasopressin formulations, with ongoing biosimilar development in other regions.
- US Medicaid and Medicare reimbursement policies will continue to affect end-user net prices.
- European Medicines Agency (EMA) oversight aligns similar regulations across Europe.
Key Takeaways
- The vasopressin market is driven by critical care needs, with regional variations in demand.
- Price declines are anticipated as generic versions enter the market, starting around 2027.
- Supply chain stability and regulatory environments will impact pricing and availability.
- Hospital procurement strategies significantly influence net prices.
- The overall market is expected to grow modestly, with a CAGR of approximately 3-4% over the next five years.
FAQs
Q1: When are generic vasopressin products likely to enter the market?
A1: Market entry of generics could occur within 3-5 years, closely linked to patent expirations expected around 2027.
Q2: How will reimbursement policies impact the price of NDC 72485-0630?
A2: Reimbursement policies can lower hospital acquisition costs and influence net prices, especially in markets with negotiated rates.
Q3: Are there regional differences in supply or demand?
A3: Yes. The US and Europe dominate demand, with Asia-Pacific showing rapid growth due to expanding healthcare infrastructure.
Q4: What factors could disrupt current price projections?
A4: Supply chain constraints, regulatory changes, or new formulations could alter pricing dynamics.
Q5: Is there potential for new indications influencing the demand?
A5: If new critical care applications or formulations are approved, demand could increase, impacting prices favorably.
References
[1] MarketWatch. (2022). Vasopressin market analysis. Retrieved from https://www.marketwatch.com
[2] GlobalData. (2022). Critical care drugs report. Retrieved from https://www.globaldata.com
[3] IQVIA. (2022). Healthcare and Rx trends.
[4] United States Food & Drug Administration (FDA). (2021). Vasopressin approvals and indications.
[5] European Medicines Agency (EMA). (2022). Medical product regulations.
